฿162.50
-฿2.00(-1.21%)
data.updated
v2.stock.overview v2.daily.trading v2.range.52w
key.stats
yesterday.close฿163.81
market.size฿34.54B
volume.trade217.42K
pe.ratio-29.12
div.yield0.00%
diluted.eps5.98
net.income-฿1.27B
revenue฿606.42M
earnings.date2026-05-14
eps.estimate0.96
rev.estimate฿303.43M
shares.out210.86M
beta1.101
about.stock
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. Insmed Incorporated was founded in 1988 and is headquartered in Bridgewater, New Jersey.
sectorHealthcare
industryBiotechnology
ceoWilliam H. Lewis
headquartersBridgewater,NJ,US
websitehttps://www.insmed.com
employees1.66K
avg.revenue฿364.43K
income.per.emp-฿767.29K
stock.faq
stock.price
x
current.stats
52w.range.q
x
pe.ratio.q
x
market.cap.q
x
eps.recent.q
x
buy.sell.q
x
price.factors
x
buy.how
x
risk.warn
risk.notice
disclaimer2
risk.disclosure
